AEMD | Aethlon Medical, Inc. Researchers Published In Journal Of Translational Medicine

More Penny Stocks News From The OTCBB

Jul 24, 2008 7:00:00 AM


Aethlon Medical, Inc. (OTCBB:AEMD) disclosed today that a peer reviewed scientific paper coauthored by Aethlon researchers has been published in the Journal of Translational Medicine. The paper entitled, "Exosomes as a Tumor Immune Escape Mechanism: Possible Therapeutic Implications" discusses the mechanism by which exosomes released by cancerous tumors are able to kill off immune cells in cancer patients. The paper further discusses the novel therapeutic approach of the Aethlon Hemopurifier(R) to capture and inhibit the spread of such immunosuppressive exosomes in cancer patients. The abstract and complete article are available to be accessed online at:

"As we continue to progress the infectious disease applications of our Hemopurifier(R), the Journal of Translational Medicine publication recognizes and reinforces the additional potential of the Hemopurifier(R) within the $43 billion cancer therapy market," stated Aethlon Chairman and CEO, James A. Joyce. "We thank the numerous researchers who participated in coauthoring the paper with our research team," concluded Joyce.

Aethlon previously disclosed that researchers discovered that the Hemopurifier(R) is effective in capturing exosomes that are released by solid tumors, lymphomas, and leukemia. Exosomes induce T-cell apoptosis (programmed cell death), and block T-cell signaling, proliferation, and cytokine production. High concentrations of circulating exosomes correlate with reduced T-cell production and tumor progression in cancer patients. In studies led by Dr. Douglas Taylor at the University of Louisville, 60% of circulating exosomes were removed from the blood of ovarian cancer patients during first pass (approximately 10-minutes) through a small scale Hemopurifier(R). The capture data was consistent over the course of five different in vitro blood studies. The ability to reduce circulating exosomes would likely reverse immune suppression and increase patient responsiveness to both immunotherapy and chemotherapy. Dr. Taylor is a recognized authority on the causative effects of immune suppression in cancer patients. He is credited with the initial characterization of exosomes and is the leading peer reviewed author on the subject.